Cancer Focus
Emerging managerBuilt from this firm's Form D filings. The firm files no SEC adviser report.
- HQ
- LA
Cancer Focus Fund combines decades of venture capital experience with the research and clinical trials expertise of MD Anderson. Its portfolio includes companies working on cancer treatments such as nectin-targeted immunotherapies, precision oncology drugs, synthetic immune therapies, CAR-T cell therapies, and radioligands, along with Mereo BioPharma, which develops therapeutics for rare diseases. Jonathan Fassberg, co-founder and Managing Partner at astr partners, serves on the Investment Committee.
01 · Says / Does
| Tag | Says | Does |
|---|---|---|
| Stages | Not stated | Not enough dated deals |
| Sectors | Biotech | Not enough dated deals |
| Regions | Not stated | Not enough dated deals |
Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.
02 · Fund history
| Fund | Year | Size | Status |
|---|---|---|---|
| Cancer Focus Fund II, LP | 2025 | $22.56M to $250M (Form D) | Raising |
03 · People across funds
- Ross Barrett, Managing Member of the General Partner of the Issuer
Cancer Focus Fund II, LP (Named on Form D)
- Jaime Aguirre, Advisor
Cancer Focus Fund II, LP (Team)
- Jonathan Fassberg, Investment Committee
Cancer Focus Fund II, LP (Team)
04 · Recent deals
No dated deals found yet.
05 · Latest from the firm
No news from the firm's website yet.
06 · Sources
- https://www.cancerfocusfund.com
- https://www.cancerfocusfund.com/
- https://www.cancerfocusfund.com/investment-team
Fund dates and sizes are from SEC Form D filings.
Last verified: Oct 28, 2026